Risk Materials

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

Cubicin (daptomycin): Important safety information to minimise the risk of myotoxicity and dysregulation of in vivo coagulation- Dosage Card for Physicians

Under the Cubicin Marketing Authorisation, MSD are required to ensure that all HCPs likely to treat patients with daptomycin are provided with risk minimisation materials. This document contains key information to help minimize the risks of myotoxicity and dysregulation of in vivo coagulation. It also provides dosage recommendations and calculates the dose of daptomycin 50 mg/ml solution that is required from the weight of the patient. The licensed indications have been extended to include paediatric patients with S. aureus bacteraemia associated with cSSTI aged from 1 to 17 years of age. The document has been updated to include information on use in this population. If you require further information and hard copies of the material please contact [email protected] If you have any questions or require additional information, please call MSD Medical Information Services on 01992 467272.

For Healthcare Professionals

Cubicin (daptomycin): Important safety information to minimise the risk of reduced susceptibility of S.aureus to daptomycin- The Laboratory Susceptibility Testing Leaflet

As part of the terms of the Marketing Authorisation for Cubicin, MSD are required to ensure that all Healthcare Professionals who are likely to treat patients with daptomycin are provided with risk minimisation materials. This document contains key information to help minimise the risk of reduced susceptibility of S.aureus to daptomycin. It also provides a detailed explanation of the susceptibility testing issues, including the need for calcium in the testing medium. The leaflet has been updated as follows: •Deletion of the reason why the BBL™ Mueller-Hinton test method is recommended in the E test section •Throughout the text, the range fort the Ca2+ concentration has also been displayed in ‘mmol/L’ •References updated If you require further information about daptomycin and hard copies of the material please contact [email protected] If you have any questions or require additional information, please call MSD Medical Information Services on 01992 467272.

For Healthcare Professionals

Send us feedback

If you would like to make a comment or send us feedback on this material, click here.